Evidence map›Paper›PMID 39696255›Full record

Observational studyBMC medicine2024

Coffee consumption and adverse cardiovascular events in patients with atrial fibrillation.

Vasco Iten, Elena Herber, Michael Coslovsky, Elisa Hennings, Rebecca E Paladini, Tobias Reichlin, Nicolas Rodondi, Andreas S Müller, Annina Stauber, Juerg H Beer and 14 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02105844 (Swiss Atrial Fibrillation Cohort Study - SWISS AF), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02105844 active not recruitingnot on this map

Swiss Atrial Fibrillation Cohort Study - SWISS AF

TypeobservationalSponsorUniversity Hospital, Basel, SwitzerlandRan2014 to 2030Enrolled2,415ConditionsAtrial Fibrillation
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Vasco ItenCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Elena HerberCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Michael CoslovskyCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Elisa HenningsCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Rebecca E PaladiniCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Tobias ReichlinDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Nicolas RodondiDepartment of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Andreas S MüllerDepartment of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland.
Annina StauberDepartment of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland.
Juerg H BeerDepartment of Medicine, Cantonal Hospital of Baden and Molecular Cardiology, University Hospital of Zurich, Zurich, Switzerland.
Roman BrennerDepartment of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Giulio ConteDivision of Cardiology, Cardiocentro Ticino Insitute, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Richard KobzaDepartment of Cardiology, Kantonsspital Luzern, Luzern, Switzerland.
Marcello Di ValentinoDepartment of Cardiology, Ospedale San Giovanni, Bellinzona, Switzerland.
Patricia Chocano BedoyaInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Freschteh MoradiCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Tim SinneckerDepartment of Biomedical Engineering, University of Basel, Medical Image Analysis Center (MIAC AG), Basel, Switzerland.
Leo H BonatiDepartment of Neurology and Stroke Center, University Hospital Basel, University of Basel, Basel, Switzerland.
Michael KühneCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Stefan OsswaldCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
David ConenPopulation Health Research Institute, McMaster University, Hamilton, Canada.
Stefanie Aeschbacher *Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland. stefanie.aeschbacher@usb.ch.
Christine S Zuern *Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland. christinestefanie.meyer-zuern@usb.ch.
Swiss-AF and Beat-AF Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is some evidence of reduced major cardiovascular event (MACE) rates associated with moderate coffee consumption in the general population. However, there is concern about the potential risks of coffee consumption in patients with atrial fibrillation (AF). Therefore, we aimed to investigate the association between coffee consumption and MACE in AF patients.

methodsData of patients with documented AF enrolled in two large prospective observational multicenter cohort studies (Swiss-AF and Beat-AF) were analyzed. Follow-up information was obtained on a yearly basis. Coffee consumption was categorized into two main groups: "daily" and "not-daily" coffee consumers as well as additional subcategories. The primary endpoint was MACE, defined as a composite of stroke or systemic embolism, myocardial infarction, hospitalization for acute heart failure, and cardiovascular mortality. Secondary endpoints were the individual components of MACE and all-cause mortality. We performed time-updated multivariable adjusted Cox regression analyses to investigate the association between coffee consumption and MACE.

resultsThe incidence rate for MACE was 5.09 per 100 person-years (py) in daily and 7.49 per 100 py in not-daily consumers (median follow-up duration: 4.7 years). After adjustment for pre-selected confounding variables, daily coffee consumption was associated with a 23% lower hazard for MACE compared to not-daily consumption (hazard ratio (HR) (95% confidence interval (CI)) 0.77 (0.66; 0.89)). Patients with moderate coffee consumption (2-3 cups/day) had the lowest hazard for MACE compared to patients with not-daily coffee consumption (HR (95% CI) 0.74 (0.63; 0.87)).

conclusionsIn a population of AF patients, daily coffee consumption was associated with a reduced risk for MACE, hospitalization for acute heart failure, and all-cause mortality. The results were inconclusive for stroke or systemic embolism, myocardial infarction, and cardiovascular death. In this analysis, we found no evidence of an unfavourable association of daily coffee consumption in AF Patients with adverse outcome events.

trial registrationClinicalTrials.gov Identifier: NCT02105844.

Indexed as

Atrial FibrillationCoffeeAgedAged, 80 and overCardiovascular DiseasesFemaleHospitalizationHumansIncidenceMaleMiddle AgedProspective StudiesCoffeeAll-cause mortalityAtrial fibrillationCaffeineCoffeeMACEOutcome events

Identifiers

PMID39696255
PMCPMC11657746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.